Pharmaceutical Cleanroom Design Guide

I. Core Design Principles of Global Pharmaceutical Cleanrooms (Adapting to International Standards) The core objective of global pharmaceutical cleanroom design is to "control contamination, ensure sterility, and prevent cross-contamination." All design phases must be based on the ISO 14644 series of standards, ICH guidelines, and the core requirements of GMP in various countries, taking into account cross-border compliance, production efficiency, operating costs, and global adaptability. The core principles are as follows: - Global Compliance Principle: Strictly follow the ISO 14644 series of international standards (ISO 14644-1 Cleanliness Classification, ISO 14644-4 Design and Construction, ISO 14644-7 Microbial Control, etc.), conform to ICH Q9(R1) "Quality Risk Management", ICH Q10 "Pharmaceutical Quality System" and other international guidelines [3], and adapt to the specific GMP standards of different countries/regions (US FDA cGMP, EU EMA GMP, PIC/S (GMP, China GMP, etc.) Ensure the design meets the regulatory requirements of the target market, passes testing and verification by international authoritative organizations such as SGS, TÜV, and DNV, meets the compliance requirements for cross-border drug distribution, and complies with internationally aligned regional standards such as the "Design Standard for Cleanrooms in Pharmaceutical Industry" (GB50457-2019).

 Contamination and Cross-Contamination Prevention Principles: Follow the unified global pharmaceutical industry control logic, through reasonable layout, airflow organization, and pressure differential control, minimize the intrusion of contaminants such as microorganisms, suspended particles, and dust, and prevent cross-contamination between different varieties and processes. For highly allergenic, highly active, and highly toxic drugs (such as biological products, cytotoxic drugs, and β-lactam drugs), internationally accepted protection standards must be followed, adopting special protective measures such as independent workshops, negative pressure isolation, and dedicated air conditioning systems, complying with the stringent GMP requirements for the production of special drugs in various countries, and ensuring a safe and controllable production process.

 Global Adaptability Principle: The cleanroom layout and functional zoning are optimized by considering the pharmaceutical process characteristics, climate conditions, and regulatory details of different countries/regions (such as the dynamic monitoring requirements for sterile drugs in Europe and America, and the specific temperature and humidity control requirements in Southeast Asia). This ensures ease of equipment installation, operation, and maintenance, avoiding redundant design. Simultaneously, the design must consider international pharmaceutical production standardization requirements, ensuring compatibility with the production of multiple drug categories and specifications, facilitating future capacity adjustments and technology upgrades, and meeting the needs of international pharmaceutical companies' global layout and large-scale production.

 Stability and Traceability Principle: The design must consider the long-term stability and controllability of environmental parameters (temperature, humidity, pressure difference, air exchange rate, etc.), selecting purification systems and materials that meet international standards to reduce the risk of failure during operation and ensure production continuity. Furthermore, it incorporates the traceability requirements of international GMP and ICH Q9(R1), designing supporting facilities that enable full traceability of environmental parameters, equipment operation, test results, and personnel operations, meeting global regulatory verification requirements and aligning with the full-process traceability requirements for dynamic and static monitoring in sterile drug production.

 Economic Efficiency and Sustainability Principles: While meeting global compliance and production requirements, optimize design schemes, rationally control construction and operating costs, and avoid over-design; simultaneously, adhere to international green and low-carbon concepts, select energy-saving purification equipment and environmentally friendly materials, optimize energy consumption structure, and achieve a balance between cleanliness levels, production costs, and environmental requirements, adapting to the global pharmaceutical industry's sustainable development trend and complying with the environmental regulatory requirements of various countries for industrial production.

II. Global Pharmaceutical Cleanroom Classification and Core International Standards

The global pharmaceutical cleanroom classification is based on the ISO 14644-1 international standard, combined with ICH guidelines and globally accepted GMP requirements (FDA cGMP, EMA GMP, etc.). Based on the contamination risk of the drug manufacturing process, different cleanroom classes are assigned. ISO 7 cleanroom (Class 10,000) is one of the most widely used classes in the international pharmaceutical industry. It must also meet microbial control requirements and adapt to regulatory differences in different countries/regions. Specific classes and core standards are as follows:

1. Core Classification (Globally Acceptable, Applicable to the Pharmaceutical Industry)

 ISO 5 (Class 100): Suitable for high-risk operation areas, such as aseptic drug filling areas, aseptic assembly areas, and open packaging container storage areas that come into direct contact with aseptic preparations. Unidirectional flow workbenches (hoods) are required to maintain the environmental conditions. Airborne particle and microbial control requirements are extremely high, corresponding to the Class A cleanroom requirements in FDA cGMP and EMA GMP, meeting international standards for high-risk aspects of aseptic drug production.

 ISO Class 7 (Class 10,000): The most widely used class, suitable for oral solid dosage form production, pre-filling preparation of sterile drugs (vial cleaning, post-sterilization temporary storage), microbial limit testing, and medical device assembly. It balances cleanliness precision with feasibility and is the "basic cleanliness level" in the global pharmaceutical industry. It corresponds to the Class C cleanroom (static) requirements in sterile drug production and is compatible with the pharmaceutical production compliance requirements of most countries/regions. Its particle count control standards are highly consistent with traditional Class 10,000 cleanroom requirements.

ISO Class 8 (Class 100,000): Suitable for auxiliary processes such as drug raw material pretreatment, packaging material cleaning (non-direct contact with drugs), and finished product storage. It has relatively relaxed requirements for particle and microbial control, corresponding to the Class D cleanroom requirements in sterile drug production. It is the universal cleanliness level for auxiliary production processes in the global pharmaceutical industry. Its air change rate and particle count control meet internationally accepted standards for auxiliary cleanrooms.

2. Core International Compliance Standards (Pharmaceutical Industry Specific, Globally Applicable)

Particle Concentration Standard (ISO 14644-1 Globally Unified): Under static conditions in an ISO Class 7 cleanroom, ≥0.5μm suspended particles ≤352,000/m³, ≥5μm suspended particles ≤2,930/m³; under dynamic conditions, ≥0.5μm suspended particles ≤3,520,000/m³. This standard adapts to the contamination release conditions in actual production processes and is a unified core indicator for ISO Class 7 cleanrooms in the global pharmaceutical industry, consistent with the particle control requirements in GMP of various countries.

Microbiological Control Standards (Globally Accepted GMP Requirements): For ISO Class 7 cleanrooms (pharmaceutical use), airborne bacteria ≤100 CFU/m³, settling bacteria ≤10 CFU/plate. Areas directly handling pharmaceuticals require enhanced microbiological monitoring to prevent microbial contamination from affecting drug safety. This also complies with ICH Q9(R1) quality risk management requirements, allowing for flexible adjustment of monitoring frequency based on drug risk levels, and is compatible with microbiological control standards in major global pharmaceutical markets such as the US, EU, and PIC/S member countries.

Pressure Difference and Airflow Standards (Internationally Unified Standards): Pressure difference between clean and non-clean areas, and between different cleanroom levels, ≥10 Pa (some countries/regions require ≥5 Pa; regional differences must be considered during design). ISO Class 7 cleanrooms must maintain a positive pressure environment to prevent external contaminants from entering. Airflow organization adopts turbulent flow or localized unidirectional flow, with an air change rate ≥30 times/hour to ensure stable particle concentration compliance. This requirement is consistent with ISO 14644-4 and airflow control standards in various national GMP standards, while also being optimized based on traditional cleanroom air change rate specifications.

Temperature and humidity standards (globally adaptable and flexibly adjustable): Standard temperature control is 18~26℃, relative humidity 45%~65%, adjustable according to drug characteristics (e.g., antibiotics, biologics) and target market climate conditions; for example, dehumidification design can be enhanced in tropical regions, while insulation measures can be optimized in cold regions. It also meets the individualized temperature and humidity control requirements of various countries' GMP standards, ensuring stability during drug production and conforming to the internationally accepted temperature and humidity control range for pharmaceutical cleanrooms.

III. Key Design Considerations for Global Pharmaceutical Cleanrooms (Adhering to International Standards)

Pharmaceutical cleanroom design needs to cover multiple dimensions, including layout, purification systems, structural materials, personnel and material management, and safety protection. Each aspect must comply with the ISO 14644 series standards, ICH guidelines, and globally accepted GMP requirements. Key design considerations are as follows:

1. Layout Design (Core: Smooth workflow, prevention of cross-contamination, globally applicable)

Layout design must follow the globally accepted principles of "separation of people and materials" and "zoning of dirty and clean areas." It should rationally divide functional areas based on the pharmaceutical production process to avoid cross-contamination, while also adapting to the regulatory details of different countries/regions. Specific requirements include:

Clear functional zoning: Divided according to the production process into raw material pretreatment area, weighing area, preparation area, filling area, sterilization area, inspection area, and storage area. Different cleanliness levels should transition gradually, with buffer rooms and airlocks to prevent direct communication between clean and non-clean areas. Simultaneously, space should be reserved for validation and testing, meeting international GMP compliance requirements for cleanroom layouts, and optimizing the design with reference to globally accepted layout specifications for pharmaceutical companies. - Separation of Personnel and Materials: Separate personnel and material purification channels are established. Personnel must undergo procedures such as changing clothes, handwashing, disinfection, and air showers before entering the clean area, and the changing process must comply with international GMP requirements (such as cleanroom garment donning guidelines). Materials must be disinfected and dust-removed through pass-through windows (or airlocks) before entering to avoid cross-contamination between personnel and materials. Non-production items are strictly prohibited from entering the production area. This requirement is a globally standardized layout guideline for pharmaceutical cleanrooms.

Special Area Design: Dust-generating operation rooms (such as crushing, mixing, and granulation) must maintain relative negative pressure to prevent dust diffusion, and exhaust air must be purified before being discharged. Highly allergenic drugs (such as penicillin) and biological products require dedicated independent workshops and facilities, and exhaust air must undergo high-efficiency purification treatment, with exhaust vents located far from the air inlets of other air purification systems. Production areas for Class A media must be located against an external wall, separated by explosion-proof walls, and equipped with explosion-proof electrical and ventilation systems, complying with global protection standards and safety regulations for the production of special pharmaceuticals.

2. Air Purification System Design (Core: Cleanliness Achieved, Compliant with International Standards)

The air purification system is the core of ensuring the cleanroom's grade. Based on the cleanliness level and production needs, a filtration, air supply, and exhaust system compliant with ISO 14644-4 standards must be designed to ensure global compliance. Specific requirements include:

 Filtration System: A three-stage filtration system of "pre-filter + medium-efficiency filter + high-efficiency filter (HEPA)" must be adopted. The HEPA filter must have a filtration efficiency of ≥99.97% for 0.3μm particles. It should be installed at the air supply terminal and inspected regularly (replaced when the pressure difference > 250Pa) to prevent filtration failure and contamination. The selection and installation of filters must comply with international standards and be adaptable to the testing and verification requirements of different countries/regions worldwide. The selection should also be optimized with reference to traditional cleanroom filtration system specifications.

Air Supply and Exhaust Design: The ISO 7 cleanroom employs turbulent air supply, with localized unidirectional flow protection available for key operational areas (such as pre-filling preparation). The exhaust system must be matched with the supply system to ensure stable pressure differential. Dust-generating and gas-generating areas require separate exhaust systems to prevent contaminant backflow. Exhaust air from aseptic drug production areas must undergo purification treatment before discharge, complying with international standards such as FDA cGMP and EMA GMP for exhaust systems. Airflow organization is optimized based on global pharmaceutical company cleanroom system design experience.

System Validation: After installation, the cleanroom system must be validated for airflow, pressure differential, cleanliness, and microbiological indicators. Revalidation should be conducted periodically (at least once a year). The validation process must comply with ISO 14644-10 standards and ICH Q9(R1) quality risk management requirements. Validation records must be archived for future reference to ensure long-term stable system operation, meet global regulatory audit requirements, and comply with GMP compliance requirements for cleanroom system validation in various countries.

3. Other Key Design Considerations (Globally Compatible)

 Structure and Materials: Utilize seamless, corrosion-resistant, and easy-to-clean wall, floor, and ceiling materials (such as stainless steel and epoxy resin coatings) to prevent particle accumulation and growth. Material selection must comply with international environmental standards and pharmaceutical industry requirements, adapting to environmental regulations in different countries/regions. The junctions between cleanroom walls, ceilings, and floors should ideally be curved to reduce dust accumulation dead zones, conforming to global pharmaceutical cleanroom structural design standards.

 Personnel and Material Management: Design personnel changing and disinfection processes that meet international GMP requirements, equipped with dedicated cleanroom garment storage rooms and handwashing and disinfection facilities. Material transfer must employ internationally standardized pass-through windows and airlocks, with material buffer zones to prevent the introduction of external contaminants. Simultaneously, incorporate global pharmaceutical industry personnel training and material control standards to ensure daily operations comply with international standards and meet the GMP requirements for personnel and material management in various countries.

 Detection and Monitoring: Design a real-time online monitoring system to monitor indicators such as temperature, humidity, pressure difference, particle concentration, and microorganisms 24 hours a day. Data can be uploaded and stored in real time, enabling full traceability. The setting of monitoring points must comply with the ISO 14644-1 standard and be adapted to the regulatory requirements of different countries/regions. At the same time, refer to the ICH Q9(R1) quality risk management requirements to strengthen monitoring of high-risk links and ensure that the cleanroom environment continuously meets the standards.